MANE
HEALTHCAREVeradermics Inc
$109.77-5.03 (-4.38%)PRE
Live · NYSE · May 9, Close
AI Insight
What's Moving MANE Today?
No stock-specific AI insight has been generated for MANE yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$32.00$117.71
$109.77
Fundamentals
Market Cap$4.6B
P/E Ratio—
EPS$-2.38
Dividend Yield—
Dividend / Share—
ROE-0.7%
Profit Margin—
Debt / Equity—
Trading
Volume902K
Avg Volume (10D)—
Shares Outstanding41.5M
MANE News
20 articles- MANE Study 302: Veradermics Posts Positive Top-Line Phase II/III Results for Oral Minoxidil PillMarketbeat·May 3, 2026
- Veradermics (MANE) Reports Positive Phase 2/3 Results for Male Pattern Hair Loss Treatment VDPHL01Yahoo Finance·Apr 30, 2026
- Veradermics Announces Pricing of Upsized Public Offering and Private PlacementYahoo Finance·Apr 30, 2026
- Newly Listed Veradermics Hair Loss Drug Shows Hair Growth GainsYahoo Finance·Apr 29, 2026
- Midday Fly By: Verizon reports ‘beat and raise,’ Shell to acquire ARCYahoo Finance·Apr 28, 2026
- Veradermics Announces Launch of Public OfferingYahoo Finance·Apr 27, 2026
- Biotech Skyrockets Nearly 50% On A Potential Game-Changer In Hair LossYahoo Finance·Apr 27, 2026
- Veradermics Shares Jump 17% on Promising Hair Loss Trial ResultsAdvfn·Apr 27, 2026
- Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 ‘302’ Clinical Trial in Male Pattern Hair LossYahoo Finance·Apr 27, 2026
- Veradermics to Hold Conference Call to Discuss Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 in Males with Mild-to-Moderate Pattern Hair LossYahoo Finance·Apr 26, 2026
- Assessing Veradermics (MANE) Valuation After Strong Year To Date Gains And Recent PullbackYahoo Finance·Apr 23, 2026
- Jim Cramer on Veradermics: “It’s Double or Nothing With MANE”Yahoo Finance·Apr 16, 2026
- Veradermics (MANE) Reports Q4 Net Loss of $21.8MYahoo Finance·Apr 12, 2026
- Veradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical UpdatesYahoo Finance·Mar 30, 2026
- Veradermics Announces Presentations on VDPHL01 and Patient Experiences With Pattern Hair Loss at 2026 American Academy of Dermatology Annual MeetingYahoo Finance·Mar 18, 2026
- Is Veradermics (MANE) Pricing Look Attractive After Recent Pharma Sector Reappraisal?Yahoo Finance·Mar 11, 2026
- Veradermics to Participate in Upcoming March Investor ConferencesYahoo Finance·Mar 3, 2026
- For the first time in decades, new hair-loss treatments are in the works. Here’s how they’re different.MarketWatch·Feb 26, 2026
- NYSE Content Update: Forgent Power Solutions, Post IPO, to Ring Opening BellYahoo Finance·Feb 12, 2026
- Assessing Veradermics (MANE) Valuation After Recent Share Price Move And Persistent Pre Revenue LossesYahoo Finance·Feb 10, 2026
All 20 articles loaded
Price Data
Open$0.00
Previous Close$114.80
Day High$0.00
Day Low$0.00
52 Week High$117.71
52 Week Low$32.00
52-Week Range
$32.00$117.71
$109.77
Fundamentals
Market Cap$4.6B
P/E Ratio—
EPS$-2.38
Dividend Yield—
Dividend / Share—
ROE-0.7%
Profit Margin—
Debt / Equity—
Trading
Volume902K
Avg Volume (10D)—
Shares Outstanding41.5M
About Veradermics Inc
Veradermics, Incorporated is a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company is headquartered in New Haven, Connecticut.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNYSE
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—